Categories: News

Viridian Therapeutics to Participate in the Wedbush PacGrow Healthcare Virtual Conference

BOULDER, Colo., Aug. 05, 2021 (GLOBE NEWSWIRE) — Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies, today announced that Jonathan Violin, Ph.D., President and Chief Executive Officer, and Barrett Katz, M.D., M.B.A., Chief Medical Officer of Viridian, will participate in a panel presentation at the Wedbush PacGrow Healthcare Virtual Conference, which is scheduled to take place from August 10 – 11, 2021.

Event: The Wedbush PacGrow Healthcare Virtual Conference
Panel: TED Talk – State of Play in Thyroid Eye Disease (TED)
Date: Wednesday, August 11th
Fireside Chat Time: 1:45 p.m. ET

Webcast information for this event will be accessible on the Events page under the Investors section of the Viridian Therapeutics website at www.viridiantherapeutics.com. A replay of this panel will be archived on the website and available for approximately 90 days following the live event.

About Viridian Therapeutics

Viridian Therapeutics is a biotechnology company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies. Viridian’s most advanced program, VRDN-001, is an anti-IGF-1R monoclonal antibody in development for TED, a debilitating auto-immune disease that causes inflammation and fibrosis within the orbit of the eye which can cause double vision, pain, and potential blindness. Patients with severe disease often require multiple remedial surgeries to the orbit, eye muscles, and eyelids. Viridian is based in Boulder, Colorado, and Waltham, Massachusetts. Learn more about Viridian and its programs at https://www.viridiantherapeutics.com/.

Follow us on Twitter @ViridianThera and on LinkedIn.

Viridian Contacts:
Investors:
Dan Ferry
LifeSci Advisors
617-430-7576
IR@viridiantherapeutics.com

Media:
Darby Pearson
Verge Scientific Communications
703-587-0831
PR@viridiantherapeutics.com

Staff

Recent Posts

Restart Life Receives Aggregate Gross Proceeds of Approximately $590,000 from Warrant Exercises and Loan

Vancouver, British Columbia--(Newsfile Corp. - December 22, 2025) - Restart Life Sciences Corp. (CSE: HEAL)…

1 hour ago

FlyteHealth to Expand Direct Access to Obesity Management Medication for Employers

NEW CANAAN, Conn., Dec. 22, 2025 /PRNewswire/ -- FlyteHealth, a national leader in integrated cardio-kidney-metabolic care,…

1 hour ago

10 Days, 10 Ways to Spend FSA (Flexible Spending Account) Funds Before the December 31 Use-It-or-Lose-It Deadline, from FSA Store®

The clock is ticking on 2025 FSA funds, and as the use-it-or-lose-it deadline approaches, FSA…

1 hour ago

TraceLink Wins 2025 Merit Award — Recognized for Healthcare Innovation for the Third Consecutive Year

TraceLink has been named a winner of the 2025 Merit Awards for Healthcare Innovation, marking…

1 hour ago

NUCALM CELEBRATES RECORD-BREAKING DECEMBER WITH OVER 2 BILLION MINUTES USED AND LARGEST LIVE EVENT ACTIVATION EVER

Tony Robbins' "Date with Destiny" Event Drives Unprecedented Engagement with NuCalm TechnologyPALM BEACH, Fla., Dec.…

1 hour ago

Point-of-Care Is Just the Beginning: Doceree 360 Report Maps Three Strategic Imperatives for HCP Engagement Across All Digital Touchpoints

New Annual Report Reveals Opportunity for Pharma Marketers to Reach Physicians Throughout Entire Decision-Making Journey—From Learning…

1 hour ago